TenX Keane Acquisition Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Xiaofeng Yuan
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 500 Fifth Avenue New York City NY United States of America 10110
- IPO Date
- Oct 14, 2022
- CIK
- 0001851484
- Website
- tenxkeane.com
- Similar Companies
- Business
- TenX Keane Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in 2021 and headquartered in New York, New York. The company was formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a focus on target companies operating in Asia excluding mainland China, Hong Kong, and Macau. TenX Keane Acquisition itself does not have significant direct operations or products as it functioned primarily as a blank check entity. In August 2024, TenX Keane Acquisition Corp. completed a reverse merger transaction with the oncology subsidiary of Citius Pharmaceuticals, resulting in the formation of Citius Oncology, Inc., which began trading on the Nasdaq stock exchange. As part of this merger, TenX Keane Acquisition was renamed Citius Oncology, Inc. Following the transaction, Citius Pharmaceuticals holds approximately 90% ownership of the newly public combined entity. The new company focuses on the development and commercialization of oncology therapies, with its primary product being LYMPHIR, an FDA-approved treatment for adults with relapsed or refractory cutaneous T-cell lymphoma following at least one prior systemic therapy. Citius Oncology also explores additional oncology assets and maintains a robust pipeline supported by intellectual property protections including orphan drug designation and pending patents. Citius Pharmaceuticals, through this merger, has gained greater financial and strategic flexibility to advance critical care biopharmaceutical assets beyond oncology, including its novel Mino-Lok antibiotic lock solution targeting a large market segment. The transaction strategically positioned the combined company to enhance market presence in oncology while enabling Citius Pharmaceuticals to concentrate on expanding other healthcare portfolios. Thus, TenX Keane Acquisition Corp., originally a blank check company targeting Asian businesses for mergers, now operates as Citius Oncology, a Nasdaq-listed biopharmaceutical company specializing in oncology products with a key focus on LYMPHIR and a commitment to developing targeted cancer therapies and critical care solutions.
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination
TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination